Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    "methodist hospital" AND ebv-specific cytotoxic t-lymphocyte | Open Studies | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Conditions: Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
Interventions: Biological: MABEL CTLs;   Drug: Cyclophosphamide;   Drug: Fludarabine
2 Recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Interventions: Genetic: DNR.NPC-specific T cells;   Genetic: DNR.NPC-specific T cells + cyclophosphamide + fludarabine
3 Not yet recruiting Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Conditions: NonHodgkin Lymphoma;   Lymphoproliferative Disorders;   EBV Related Lymphoma;   EBV-Related PTLD;   Hodgkin Lymphoma;   EBV Related Non-Hodgkin's Lymphoma;   EBV Related Hodgkin's Lymphoma
Interventions: Biological: EB-VST Cells;   Biological: Nivolumab

Study has passed its completion date and status has not been verified in more than two years.